Publicacions (58) Publicacions en què ha participat algun/a investigador/a

2024

  1. Anti-miR-873-5p improves alcohol-related liver disease by enhancing hepatic deacetylation via SIRT1

    JHEP Reports, Vol. 6, Núm. 1

  2. Breaking the barriers: the role of gut homeostasis in Metabolic-Associated Steatotic Liver Disease (MASLD)

    Gut Microbes, Vol. 16, Núm. 1

  3. Cirrhosis-downregulated LSECtin can be retrieved by cytokines, shifts the TLR-induced LSECs secretome and correlates with the hepatic Th response

    Liver International, Vol. 44, Núm. 4, pp. 996-1010

  4. Control compounds for preclinical drug-induced liver injury assessment: Consensus-driven systematic review by the ProEuroDILI network

    Journal of Hepatology

  5. Curcumin encapsulated in milk small extracellular vesicles as a nanotherapeutic alternative in experimental chronic liver disease

    Biomedicine and Pharmacotherapy, Vol. 173

  6. Fecal microbiota transplantation from female donors restores gut permeability and reduces liver injury and inflammation in middle-aged male mice exposed to alcohol

    Frontiers in Nutrition, Vol. 11

  7. Inhibition of ALK3-mediated signalling pathway protects against acetaminophen-induced liver injury

    Redox Biology, Vol. 71

  8. Proceedings of the 5th Meeting of Translational Hepatology, organized by the Spanish Association for the Study of the Liver (AEEH)

    Gastroenterologia y Hepatologia

  9. Roadmap to DILI research in Europe. A proposal from COST action ProEuroDILINet

    Pharmacological Research, Vol. 200

  10. Seladelpar: New hope for patients with primary biliary cholangitis

    Med

  11. p63 controls metabolic activation of hepatic stellate cells and fibrosis via an HER2-ACC1 pathway

    Cell Reports Medicine, Vol. 5, Núm. 2

2023

  1. A Novel Mouse Model of Combined Hepatocellular-Cholangiocarcinoma Induced by Diethylnitrosamine and Loss of Ppp2r5d

    Cancers, Vol. 15, Núm. 16

  2. Advancing with cancer immunotherapeutics: CD29+ regulatory T cell antagonism

    Gut

  3. Expression of Cyclin E1 in hepatic stellate cells is critical for the induction and progression of liver fibrosis and hepatocellular carcinoma in mice

    Cell Death and Disease, Vol. 14, Núm. 8

  4. Expression of HMGCS2 in intestinal epithelial cells is downregulated in inflammatory bowel disease associated with endoplasmic reticulum stress

    Frontiers in immunology, Vol. 14, pp. 1185517

  5. Hepatocyte dedifferentiation profiling in alcohol-related liver disease identifies CXCR4 as a driver of cell reprogramming

    Journal of Hepatology, Vol. 79, Núm. 3, pp. 728-740

  6. JNKs protect from cholestatic liver disease progression by modulating Apelin signalling

    JHEP Reports, Vol. 5, Núm. 11

  7. Lack of Cyclin E1 in hepatocytes aggravates ethanol-induced liver injury and hepatic steatosis in experimental murine model of acute and chronic alcohol-associated liver disease

    Biochimica et Biophysica Acta - Molecular Basis of Disease, Vol. 1869, Núm. 4

  8. Mouse Models for Hepatic Stellate Cell Activation and Liver Fibrosis Initiation

    Methods in molecular biology (Clifton, N.J.), Vol. 2669, pp. 177-191

  9. Neuroblastoma RAS viral oncogene homolog (N-RAS) deficiency aggravates liver injury and fibrosis

    Cell death & disease, Vol. 14, Núm. 8, pp. 514